0000000000304635

AUTHOR

G Punzi

showing 16 related works from this author

Limits on neutral Higgs boson production in the forward region in $pp$ collisions at $\sqrt{s} = 7$ TeV

2013

Limits on the cross-section times branching fraction for neutral Higgs bosons, produced in p p collisions at root s = 7 TeV, and decaying to two tau leptons with pseudorapidities between 2.0 and 4.5, are presented. The result is based on a dataset, corresponding to an integrated luminosity of 1.0 fb(-1), collected with the LHCb detector. Candidates are identified by reconstructing final states with two muons, a muon and an electron, a muon and a hadron, or an electron and a hadron. A model independent upper limit at the 95% confidence level is set on a neutral Higgs boson cross-section times branching fraction. It varies from 8.6 pb for a Higgs boson mass of 90 GeV to 0.7 pb for a Higgs bos…

GravitacióSEARCH; MSSM; LHCHadronStandard-model Higgs boson7. Clean energy01 natural sciencesHigh Energy Physics - ExperimentSettore FIS/04 - Fisica Nucleare e SubnucleareHigh Energy Physics - Experiment (hep-ex)[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Teoria quànticaNuclear ExperimentQCBosonPhysicsHiggs physicsQuantum field theoryHiggs bosonProduction (computer science)Física nuclearLHCHadron-induced high- and super-high-energy interactions (energy > 10 GeV): Inclusive production with identified leptons photons or other nonhadronic particlesParticle Physics - ExperimentGravitationParticle physicsTeoria quàntica de campsNuclear and High Energy PhysicsFOS: Physical sciencesStandard-model Higgs bosons; Supersymmetric Higgs bosons; Hadron-induced high- and super-high-energy interactions (energy > 10 GeV): Inclusive production with identified leptons photons or other nonhadronic particlesHadronsPartícules (Física nuclear)Standard ModelSEARCH0103 physical sciences010306 general physicsLarge Hadron Collider (France and Switzerland)Standard-model Higgs bosonsMuonHadron-Hadron Scattering010308 nuclear & particles physicsBranching fractionComputer Science::Information RetrievalHadron-Hadron Scattering; Higgs physicsHigh Energy Physics::PhenomenologyGran Col·lisionador d'HadronsHiggs physicSupersymmetric Higgs bosonSupersymmetric Higgs bosonsQuantum theoryHadron-Hadron Scattering; Higgs physics; Nuclear and High Energy PhysicsHigh Energy Physics::ExperimentMSSMLepton
researchProduct

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

2012

Prevalence and predictors of transmitted drug resistance (TDR), defined as the presence of at least one WHO surveillance drug resistance mutation (SDRM), were investigated in antiretroviral-naïve HIV-1-infected patients, with a genotypic resistance test (GRT) performed ≤6months before starting cART between 2000 and 2010. 3163 HIV-1 sequences were selected (69% subtype B). Overall, the prevalence of TDR was 12% (13.2% subtype B, 9% non-B). TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR. © 2012 The Authors. Clinical Microbiol…

AdultMaleMicrobiology (medical)CartDrugmedicine.medical_specialtyGenotypeAnti-HIV Agentsmedia_common.quotation_subjectHuman immunodeficiency virus (HIV)HIV InfectionsDrug resistancemedicine.disease_causeArticleEvolution Molecular03 medical and health sciencesrecent HIV infection0302 clinical medicineInternal medicineDrug Resistance ViralPrevalencemedicineHumansHIV Infection030212 general & internal medicinemedia_common0303 health scienceschronic HIV infection030306 microbiologybusiness.industryAntiretroviral therapy; Chronic HIV infection; Recent HIV infection; Resistance epidemiology; Transmitted resistance; Microbiology (medical); Infectious DiseasesAnti-HIV AgentGeneral MedicineMiddle Agedtransmitted resistanceVirologyAntiretroviral therapy3. Good healthAntiretroviral therapyInfectious DiseasesItalyHIV-1Genotypic resistanceFemalebusinessHumanresistance epidemiologyClinical Microbiology and Infection
researchProduct

Higgs boson studies at the Tevatron

2013

We combine searches by the CDF and D0 Collaborations for the standard model Higgs boson with mass in the range 90-200 GeV/c2 produced in the gluon-gluon fusion, WH, ZH, tt̄H, and vector boson fusion processes, and decaying in the H→bb̄, H→W+W-, H→ZZ, H→τ+τ-, and H→γγ modes. The data correspond to integrated luminosities of up to 10 fb-1 and were collected at the Fermilab Tevatron in pp̄ collisions at √s=1.96 TeV. The searches are also interpreted in the context of fermiophobic and fourth generation models. We observe a significant excess of events in the mass range between 115 and 140 GeV/c2. The local significance corresponds to 3.0 standard deviations at mH=125 GeV/c2, consistent with the…

FERMILAB TEVATRON COLLIDERNuclear and High Energy PhysicsParticle physicsproton antiproton collisions; FERMILAB TEVATRON COLLIDER; Standard Model Higgs boson; BROKEN SYMMETRIESSTANDARD MODELP(P)OVER-BAR COLLISIONSTevatronFOS: Physical sciencesContext (language use)ATLAS DETECTORddc:500.2Standard Model Higgs boson7. Clean energy01 natural sciencesStandard ModelVector bosonHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)SEARCH0103 physical sciencesBibliography[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]BROKEN SYMMETRIESFermilab010306 general physicsPhysicsHIGGS BOSONB-JET IDENTIFICATIONLarge Hadron ColliderPP COLLISIONS010308 nuclear & particles physics4. EducationHigh Energy Physics::PhenomenologyROOT-S=1.96 TEVPARTON DISTRIBUTIONSExperimental High Energy PhysicsHiggs bosonproton antiproton collisionsComputingMethodologies_DOCUMENTANDTEXTPROCESSINGSYMMETRIESCDFB-JET IDENTIFICATION; STANDARD MODEL; ATLAS DETECTOR; PP COLLISIONS; P(P)OVER-BAR COLLISIONS; PARTON DISTRIBUTIONS; ROOT-S=1.96 TEV; SEARCH; LHC; SYMMETRIESHigh Energy Physics::ExperimentLHC
researchProduct

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.

2012

Introduction: This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients. Results: Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the ma…

MaleTime FactorsCross-sectional studyHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeCohort StudiesAntiretroviral Therapy Highly ActiveRitonavir-boosted darunavirGenotypeHIV InfectionTreatment FailureViralGenotypic resistanceDarunavirSulfonamidesGeneral MedicineMiddle AgedVirological failureInfectious DiseasesFemaleHumanmedicine.drugAdultMicrobiology (medical)Logistic ModelTime FactorGenotypeAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVESulfonamideDrug Resistance ViralmedicineHumansHighly ActiveDarunavir; Genotypic resistance; Protease inhibitors; Ritonavir-boosted darunavir; Adult; Antiretroviral Therapy Highly Active; Cohort Studies; Cross-Sectional Studies; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Sulfonamides; Time Factors; Treatment Failure; Drug Resistance Viral; Microbiology (medical); Infectious DiseasesHIV Protease InhibitorDarunavirCross-Sectional Studiebusiness.industryHIV Protease InhibitorsProtease inhibitorsAntiretroviral therapyVirologyCross-Sectional StudiesLogistic ModelsProtease inhibitorMutationGenotypic resistanceHIV-1Cohort Studiebusiness
researchProduct

Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit fro…

2009

Objectives: To test retrospectively the ability of four freely available rules-based expert systems to predict short- and medium-term virological outcome following an antiretroviral treatment switch in pre-treated HIV-1 patients. Methods: The HIV-1 genotype interpretation systems (GISs) HIVdb, ANRS, Rega and AntiRetroScan were tested for their accuracy in predicting response to highly active antiretroviral therapy using 8 week (n = 765) and 24 week (n = 634) follow-up standardized treatment change episodes extracted from the Italian Antiretroviral Resistance Cohort Analysis (ARCA) database. A genotypic sensitivity score (GSS) was derived for each genotype-treatment pair for the different GI…

Maleinterpretation systemHIV InfectionsDrug resistanceLogistic regressionRetrospective StudieHIV InfectionPharmacology (medical)Microbial Sensitivity TestMiddle AgedPrognosisgenotype drug resistance algorithmAlgorithmTreatment OutcomeInfectious DiseasesItalyRNA ViralFemaleCohort studyHumanMicrobiology (medical)Adultmedicine.medical_specialtyGenotypeLogistic ModelAnti-HIV AgentsPrognosiantiretroviralMicrobial Sensitivity TestsInternal medicinemedicinePotencyAnimalsHumansRetrospective StudiesPharmacologyReceiver operating characteristicbusiness.industryAnimalAnti-HIV AgentRetrospective cohort studyOdds ratiogenotype; interpretation system; antiretroviral; drug potency weightingWeightingLogistic ModelsROC CurveDrug resistanceImmunologyHIV-1businessdrug potency weighting
researchProduct

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study

2011

Background and objectives: Guidelines indicate a plasma HIV-1 RNA load of 500-1000 copies/mL as the minimal threshold for antiretroviral drug resistance testing. Resistance testing at lower viral load levels may be useful to guide timely treatment switches, although data on the clinical utility of this remain limited. We report here the influence of viral load levels on the probability of detecting drug resistance mutations (DRMs) and other mutations by routine genotypic testing in a large multicentre European cohort, with a focus on tests performed at a viral load <1000 copies/mL. Methods: A total of 16511 HIV-1 reverse transcriptase and protease sequences from 11492 treatment-experienced …

MaleDrug ResistanceHIV InfectionsDrug resistanceCohort Studies0302 clinical medicineGenotypeHIV InfectionPharmacology (medical)030212 general & internal medicineViral0303 health sciencesProteolytic enzymesGenotypic testing; HIV; Viral load; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; RNA Viral; Viral Proteins; Drug Resistance Viral; Mutation Missense; Viral Load; Pharmacology; Pharmacology (medical); Infectious DiseasesViral LoadGenotypic testing3. Good healthEuropeInfectious DiseasesCohortRNA ViralFemaleViral loadCohort studyHumanMicrobiology (medical)AdultGenotypeAnti-HIV AgentsMutation MissenseBiologySettore MED/17 - MALATTIE INFETTIVE03 medical and health sciencesViral ProteinsSDG 3 - Good Health and Well-beingDrug Resistance ViralHumansViral ProteinPharmacology030306 microbiologyHIVAnti-HIV AgentVirologyReverse transcriptaseCD4 Lymphocyte CountRegimenHIV; genotypic testing; viral loadGenotypic testing; HIV; Viral load; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance Viral; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mutation Missense; RNA Viral; Viral Load; Viral ProteinsImmunologyMutationHIV-1RNAMissenseCohort Studie
researchProduct

A novel methodology for large-scale phylogeny partition

2011

Understanding the determinants of virus transmission is a fundamental step for effective design of screening and intervention strategies to control viral epidemics. Phylogenetic analysis can be a valid approach for the identification of transmission chains, and very-large data sets can be analysed through parallel computation. Here we propose and validate a new methodology for the partition of large-scale phylogenies and the inference of transmission clusters. This approach, on the basis of a depth-first search algorithm, conjugates the evaluation of node reliability, tree topology and patristic distance analysis. The method has been applied to identify transmission clusters of a phylogeny …

Genetics and Molecular Biology (all)MalepolTheoretical computer scienceInferenceGene Products polGeneral Physics and AstronomyHIV InfectionsBiologyNetwork topologySettore MED/17 - MALATTIE INFETTIVEBiochemistryArticleGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesPhysics and Astronomy (all)0302 clinical medicineSearch algorithmphylogenetic analysis; virus transmissionGene ProductsHumansHIV Infection030212 general & internal medicinePhylogeny030304 developmental biologyAlgorithms; Classification; Female; Gene Products pol; HIV Infections; HIV-1; Humans; Male; Phylogeny; Biochemistry Genetics and Molecular Biology (all); Chemistry (all); Physics and Astronomy (all)Genetics0303 health sciencesBiochemistry Genetics and Molecular Biology (all)MultidisciplinaryPhylogenetic treeNode (networking)phylogenetic analysisChemistry (all)HIVGeneral Chemistryvirus transmissionClassificationPartition (database)AlgorithmIdentification (information)Transmission (telecommunications)HIV-1FemaleMETHODOLOGYAlgorithmsHumanNature Communications
researchProduct

Search for CP violation in D (+/-) -> (KSK +/-)-K-0 and D-s(+/-) -> K-S(0)pi(+/-) decays

2014

A search for \CP violation in Cabibbo-suppressed $D^{\pm}\rightarrow K^0_{\mathrm{S}} K^{\pm}$ and $D^{\pm}_{s}\rightarrow K^0_{\mathrm{S}} \pi^{\pm}$ decays is performed using $pp$ collision data, corresponding to an integrated luminosity of 3~fb$^{-1}$, recorded by the LHCb experiment. The individual $CP$-violating asymmetries are measured to be \begin{eqnarray*} \mathcal{A}_{CP}^{D^{\pm}\rightarrow K^0_{\mathrm{S}} K^{\pm}} & = & (+0.03 \pm 0.17 \pm 0.14) \% \mathcal{A}_{CP}^{D^{\pm}_{s}\rightarrow K^0_{\mathrm{S}} \pi^{\pm}} & = & (+0.38 \pm 0.46 \pm 0.17) \%, \end{eqnarray*} assuming that $CP$ violation in the Cabibbo-favoured decays is negligible. A combination of the measured asymmet…

Nuclear and High Energy PhysicsParticle physicsSDG 16 - Peacemedia_common.quotation_subjectCP violation; Hadron-Hadron ScatteringDalitz plotLHCb - Abteilung HofmannHadrons01 natural sciencesAsymmetryNOSettore FIS/04 - Fisica Nucleare e SubnucleareNuclear physicsTEV PP COLLISIONS; PRODUCTION ASYMMETRY0103 physical sciencesCP violation hadron-hadron scatteringPiTEV PP COLLISIONS010306 general physicsLarge Hadron Collider (France and Switzerland)PRODUCTION ASYMMETRYQCmedia_commonPhysicsLuminosity (scattering theory)Hadron-Hadron Scattering010308 nuclear & particles physicshep-exSDG 16 - Peace Justice and Strong InstitutionsHigh Energy Physics::PhenomenologyGran Col·lisionador d'HadronsParticle physicsPhi meson/dk/atira/pure/sustainabledevelopmentgoals/peace_justice_and_strong_institutionsJustice and Strong InstitutionsCP violationCP violationHigh Energy Physics::ExperimentFísica nuclearFísica de partículesExperimentsParticle Physics - Experiment
researchProduct

Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

2013

HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis. © 2013 The Author.

MaleMultivariate analysisDatabases FactualDrug ResistanceHIV InfectionsDrug resistance0302 clinical medicineRetrospective StudieRisk FactorsEpidemiologyGenotypepol Gene Products Human Immunodeficiency ViruOdds RatioPrevalenceImmunology and AllergyHIV Infection030212 general & internal medicinepol Gene ProductsViralMultivariate Analysimedia_common0303 health sciencesDrug Resistance Prevalence HIV-1Middle AgedResistance mutation3. Good healthReverse Transcriptase InhibitorEuropeInfectious DiseasesReverse Transcriptase InhibitorsepidemiologyFemaleMultipleHuman Immunodeficiency VirusHumanDrugAdultmedicine.medical_specialtyGenotypeEvolutionmedia_common.quotation_subjectSexual Behaviorantiretroviral therapyInfectious DiseaseBiologySettore MED/17 - MALATTIE INFETTIVEEvolution Molecular03 medical and health sciencesDatabasesSDG 3 - Good Health and Well-beingDrug Resistance Multiple ViralmedicineHumansHIV Protease InhibitorFactualRetrospective Studies030306 microbiologyRisk FactorMolecularRetrospective cohort studyOdds ratioHIV Protease InhibitorsCD4 Lymphocyte Countantiretroviral therapy; drug resistance; epidemiology; genotyping; HIV-1; Adult; CD4 Lymphocyte Count; Databases Factual; Europe; Evolution Molecular; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sexual Behavior; pol Gene Products Human Immunodeficiency Virus; Drug Resistance Multiple Viral; Immunology and Allergy; Infectious Diseasesgenotypingpol Gene Products Human Immunodeficiency VirusImmunologyMultivariate AnalysisMutationHIV-1DemographyJournal of Infectious Diseases
researchProduct

Measurement of polarization amplitudes and CP asymmetries in B 0 → Φk *(892)0

2014

An angular analysis of the decay $B^0 \to \phi K^*(892)^0$ is reported based on a $pp$ collision data sample, corresponding to an integrated luminosity of 1.0 fb$^{-1}$, collected at a centre-of-mass energy of $\sqrt{s} = 7$ TeV with the LHCb detector. The P-wave amplitudes and phases are measured with a greater precision than by previous experiments, and confirm about equal amounts of longitudinal and transverse polarization. The S-wave $K^+ \pi^-$ and $K^+K^-$ contributions are taken into account and found to be significant. A comparison of the $B^0 \to \phi K^*(892)^0$ and $\bar{B}^0 \to \phi \bar{K}^*(892)^0$ results shows no evidence for direct CP violation in the rate asymmetry, in th…

B physic12.15.MmB physicsLuminosityHigh Energy Physics - ExperimentSettore FIS/04 - Fisica Nucleare e SubnucleareNeutral current13.88.+ePolarization[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]TOOLmedia_commonPhysicsPhysicsPHYSICS PARTICLES & FIELDSParticle physicsCharge conjugation parity time reversal and other discrete symmetriePolarization (waves)Transverse planeAmplitudeCP violationPhysical SciencesCP violationFísica nuclearLHCParticle Physics - ExperimentParticle physicsNuclear and High Energy Physicsmedia_common.quotation_subject14.40.NdFlavour Changing Neutral CurrentsLHCb - Abteilung HofmannHadronsAsymmetryDECAYSHadronic decays of bottom mesonDISTRIBUTIONSLarge Hadron Collider (France and Switzerland)B physics; CP violation; Flavour Changing Neutral Currents; Hadron-Hadron Scattering; Polarization; Nuclear and High Energy PhysicsScience & TechnologyFlavour Changing Neutral CurrentHadron-Hadron ScatteringB physics; CP violation; Flavour Changing Neutral Currents; Hadron-Hadron Scattering; PolarizationGran Col·lisionador d'HadronsLHCb13.25.HwBottom mesons (|B|>0)11.30.ErHigh Energy Physics::ExperimentFísica de partículesExperimentsPolarization in interactions and scatteringEnergy (signal processing)Bar (unit)
researchProduct

Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART

2008

The extent to which HIV-1 proviral DNA mutations cause clinically relevant antiretroviral resistance is still controversial. Paired plasma HIV-1 RNA and whole blood DNA were compared in patients failing HAART to investigate if the additional knowledge of archived mutations could improve the selection of potentially active drugs. Seventy-three HIV-1-infected patients with first/second HAART failure were studied before starting a new regimen based on RNA genotyping. Follow-up data after a 12-week therapy were available. DNA genotyping was retrospectively performed on stored whole blood samples and mutational profiles were compared to those from RNA. The mean number of IAS pol mutations was si…

Anti-HIV AgentsDNA Mutational AnalysisMolecular Sequence DataProviral DNAHIV InfectionsHAART failuremedicine.disease_causeDNA Mutational Analysichemistry.chemical_compoundHIV ProteaseProvirusesAntiretroviral Therapy Highly ActiveVirologyDrug Resistance ViralDNA Mutational AnalysismedicineHumansMulticenter Studies as TopicHIV InfectionTreatment FailureGenotypingRandomized Controlled Trials as TopicCOLD-PCRMutationPlasma RNAbiologyProviruseSequence Analysis RNAAnti-HIV AgentRNASequence Analysis DNAbiology.organism_classificationVirologyHIV Reverse TranscriptaseReverse transcriptaseAntiretroviral genotypic resistanceInfectious DiseaseschemistryDNA ViralMutationLentivirusImmunologyHIV-1RNA ViralDNAantiretroviral genotypic resistance; haart failure; hiv-1; plasma rna; proviral dnaHumanJournal of Medical Virology
researchProduct

Low Rate of Virological Failure and Maintenance of Susceptibility to HIV-1 Protease Inhibitors with First-Line Lopinavir/Ritonavir-Based Antiretrovir…

2010

Protease inhibitor (PI)-resistant HIV-1 has hardly ever been detected at failed boosted PI-based first-line antiretroviral regimens in clinical trials. However, this phenomenon has not been investigated in clinical practice. To address this gap, data from patients starting a first-line lopinavir/ritonavir (LPV/rtv)-based therapy with available baseline HIV-1 RNA load, a viral genotype and follow-up viral load after 3 and 6 months of treatment were extracted from the Italian Antiretroviral Resistance Cohort Analysis (ARCA) observational database. Based on survival analysis, 39 (7.1%) and 43 (7.8%) of the 548 examined patient cases had an HIV-1 RNA >500 and >50 copies/ml, respectively, after …

MaleLopinavir/ritonavirHIV Infectionsboosted protease inhibitorLopinavirCohort Studies0302 clinical medicineAntiretroviral Therapy Highly Activevirologic failureHIV InfectionTreatment Failure030212 general & internal medicinePyrimidinone0303 health scienceseducation.field_of_studylopinavir/ritonavirLopinavirViral LoadResistance mutationfirst-line antiretroviral therapyReverse Transcriptase Inhibitor3. Good healthTreatment OutcomeInfectious DiseasesRNA ViralReverse Transcriptase InhibitorsMedicineDrug Therapy CombinationFemaleSurvival AnalysiViral loadHumanmedicine.drugAnti-HIV AgentsPopulationPyrimidinones.Settore MED/17 - MALATTIE INFETTIVEEmtricitabinehuman immunodeficiency virus type 103 medical and health sciencesVirologyDrug Resistance Viralantiretroviral drug resistancemedicineHumansProtease inhibitor (pharmacology)educationHIV Protease InhibitorRitonavir030306 microbiologybusiness.industryAnti-HIV AgentHIV Protease InhibitorsSurvival AnalysisVirologyHIV-1RitonavirCohort Studiebusiness
researchProduct

Angular analysis of charged and neutral B → Kμ + μ − decays

2014

The angular distributions of the rare decays B → K+µ+µ- and B0 → K0 &lt;inf&gt;a&lt;/inf&gt;Sμ+μ- are studied with data corresponding to 3 fb-1 of integrated luminosity, collected in proton-proton collisions at 7 and 8TeV centre-of-mass energies with the LHCb detector. The angular distribution is described by two parameters, FH and the forward-backward asymmetry of the dimuon system AFB, which are determined in bins of the dimuon mass squared. The parameter F&lt;inf&gt;H&lt;/inf&gt; is a measure of the contribution from (pseudo)scalar and tensor amplitudes to the decay width. The measurements of A&lt;inf&gt;FB&lt;/inf&gt; and F&lt;inf&gt;H&lt;/inf&gt; reported here are the most precise to d…

B physic12.15.MmB physicsSettore FIS/04 - Fisica Nucleare e SubnucleareLuminosityNeutral currentFlavor physicsMathematics::ProbabilityNuclear Experimentmedia_commonPhysicsB physics; Flavor physics; Flavour changing neutral currents; Hadron-hadron scattering; Rare decayPhysicsPHYSICS PARTICLES & FIELDSParticle physicsAmplitudePhysical SciencesFísica nuclearLHCNuclear and High Energy PhysicsParticle physicsmedia_common.quotation_subject14.40.NdScalar (mathematics)Flavour Changing Neutral CurrentsMathematics::Analysis of PDEsLHCb - Abteilung HofmannHadronsMeasure (mathematics)AsymmetryMathematics::Numerical AnalysisStandard ModelAngular distributionTheoryofComputation_ANALYSISOFALGORITHMSANDPROBLEMCOMPLEXITYLeptonic semileptonic and radiative decays of bottom mesonSDG 7 - Affordable and Clean EnergyTensorLarge Hadron Collider (France and Switzerland)Science & Technology/dk/atira/pure/sustainabledevelopmentgoals/affordable_and_clean_energyHadron-Hadron ScatteringGran Col·lisionador d'HadronsFlavour changing neutral currentLHCbRare decay13.20.HeFlavor physicBottom mesons (|B|>0)High Energy Physics::ExperimentFísica de partículesExperiments
researchProduct

Combination of measurements of the top-quark pair production cross section from the Tevatron Collider

2014

We combine six measurements of the inclusive top-quark pair (tt̄) production cross section (σtt̄) from data collected with the CDF and D0 detectors at the Fermilab Tevatron with proton-antiproton collisions at s=1.96TeV. The data correspond to integrated luminosities of up to 8.8fb-1. We obtain a value of σtt̄=7.60±0.41pb for a top-quark mass of mt=172.5GeV. The contributions to the uncertainty are 0.20 pb from statistical sources, 0.29 pb from systematic sources, and 0.21 pb from the uncertainty on the integrated luminosity. The result is in good agreement with the standard model expectation of 7.35-0.33+0.28pb at next-to-next-to-leading order and next-to-next-to leading logarithms in pert…

Top quarkP(P)OVER-BAR COLLISIONSTevatron7. Clean energylaw.inventionPhysics Particles & FieldsHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)law[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]HADRON COLLIDERSFERMILABFermilabNuclear ExperimentQuantum chromodynamicsPhysicsLarge Hadron ColliderPhysicsP(P)OVER-BAR COLLISIONS; ROOT-S=1.96 TEV; PARTON DISTRIBUTIONS; HADRON COLLIDERS; LEADING ORDER; T(T)OVER-BAR; DETECTOR; LHC; QCD; FERMILABPerturbative QCD3. Good healthROOT-S=1.96 TEVPhysical SciencesComputingMethodologies_DOCUMENTANDTEXTPROCESSINGLHCT(T)OVER-BARParticle physicsNuclear and High Energy PhysicsFOS: Physical sciencesAstrophysics::Cosmology and Extragalactic AstrophysicsAstronomy & AstrophysicsMASSNuclear physicsSEARCHColliderParticle PhysicsDETECTORAstrophysics::Galaxy AstrophysicsScience & Technologyhep-exLEADING ORDERHigh Energy Physics::PhenomenologyTop quarkQCDP(P)OVER-BAR COLLISIONS; T(T)OVER-BAR; DETECTOR; SEARCH; MASSPair productionPARTON DISTRIBUTIONSExperimental High Energy PhysicsCollider PhysicsCDFHigh Energy Physics::ExperimentParticle Physics; Collider Physics; Top quark
researchProduct

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

2011

An investigation was undertaken to determine whether specific pol mutations hinder long-term immune recovery regardless of virological response. In total, 826 patients with >50 HIV RNA copies/ml, who underwent genotypic resistance testing between 1 January 2000 and 31 December 2003 after >3 years of antiretroviral treatment, and were followed up for >3 years after genotypic resistance testing, were analyzed retrospectively. The outcome of the study was the lack of immune recovery after >3 years of follow-up, defined as a slope by linear regression 50 copies/ml divided by the number of HIV RNA measurements during follow-up. Logistic regression was used for univariable and multivariable analy…

MaleHIV InfectionsDrug resistanceLogistic regressionResistance to nucleoside reverse transcriptase inhibitorCD4+ T-lymphocyteRetrospective StudieImmunopathologyAntiretroviral Therapy Highly ActiveResistance to non-nucleoside reverse transcriptase inhibitorgeneticsResistance to protease inhibitorHIV Infectionresistance to nucleoside reverse transcriptase inhibitorsViralSidaresistance to protease inhibitorsbiologyReverse-transcriptase inhibitorViral LoadGenes poldrug therapy/immunology/virologyReverse Transcriptase InhibitorInfectious DiseasesTreatment Outcomeresistance to non-nucleoside reverse transcriptase inhibitorsReverse Transcriptase InhibitorsFemaleViral loadmedicine.drugHumanpolAnti-HIV AgentsAntiretroviral TherapyViremiaInfectious DiseaseSettore MED/17 - MALATTIE INFETTIVEpharmacology/therapeutic useAcquired immunodeficiency syndrome (AIDS)VirologyDrug Resistance ViralmedicineHumansHighly ActiveRetrospective StudiesAnti-HIV Agents; pharmacology/therapeutic use Antiretroviral Therapy; Highly Active CD4 Lymphocyte Count Drug Resistance; Viral; genetics Female Genes; pol HIV Infections; drug therapy/immunology/virology HIV-1; drug effects/enzymology/genetics Humans Male Mutation Retrospective Studies Reverse Transcriptase Inhibitors; therapeutic use Treatment Outcome Viral Loaddrug resistanceAnti-HIV Agentbiology.organism_classificationmedicine.diseaseVirologyCD4 Lymphocyte CountGenesdrug effects/enzymology/geneticstherapeutic useMutationCD4+ T-lymphocytesHIV-1
researchProduct

Measurement of the B-0 -> K*(0) e(+) e(-) branching fraction at low dilepton mass

2013

The branching fraction of the rare decay B-0 -> K*(0) e(+) e(-) in the dilepton mass region from 30 to 1000 MeV/c(2) has been measured by the LHCb experiment, using pp collision data, corresponding to an integrated luminosity of 1.0 fb(-1), at a centre-of-mass energy of 7 TeV. The decay mode B-0 -> J/psi (e(+) e(-)) K*(0) is utilized as a normalization channel. The branching fraction B(B-0 -> K*(0) e(+) e(-)) is measured to be B(B-0 -> K*(0) e(+) e(-))(30-1000 MeV/c2) = (3.1(-0.8)(-0.3)(+0.9)(+0.2) +/- 0.2) x 10(-7) where the fi rst error is statistical, the second is systematic, and the third comes from the uncertainties on the B-0 -> J/K*(0) and J/psi -> e(+) e(-) branching fractions.

Nuclear and High Energy PhysicsParticle physicsB physicModels beyond the standard modelFlavour Changing Neutral CurrentsFOS: Physical sciencesHadrons01 natural sciencesDECAYSB physicsPartícules (Física nuclear)High Energy Physics - ExperimentSettore FIS/04 - Fisica Nucleare e SubnucleareNeutral currentHigh Energy Physics - Experiment (hep-ex)Neutral currents0103 physical sciencesLeptonic semileptonic and radiative decays of bottom meson[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]TOOLDECAYS; TOOL010306 general physicsLarge Hadron Collider (France and Switzerland)QCPhysicsFlavour Changing Neutral CurrentHadron-Hadron Scattering010308 nuclear & particles physicsBranching fractionB physics; Branching fraction; Flavour Changing Neutral Currents; Hadron-Hadron Scattering; Rare decayHigh Energy Physics::PhenomenologyGran Col·lisionador d'Hadrons3. Good healthCromodinàmica quànticaFIS/01 - FISICA SPERIMENTALERare decayB physics; Branching fraction; Flavour Changing Neutral Currents; Hadron-Hadron Scattering; Rare decay; Nuclear and High Energy PhysicsBottom mesons (|B|>0); Leptonic semileptonic and radiative decays of bottom mesons; Neutral currents; Models beyond the standard modelLeptonic semileptonic and radiative decays of bottom mesonsBottom mesons (|B|>0)Branching fractionHigh Energy Physics::ExperimentFísica nuclearDECAYParticle Physics - ExperimentQuantum chromodynamics
researchProduct